Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Briacell Therapeutics Corp BCTXW


Primary Symbol: T.BCT Alternate Symbol(s):  BCTX

Healthcare Biotechnology
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted... see more

Recent & Breaking News (TSX:BCT)

BriaCell Announces Non-Brokered Private Placement

MarketWire Canada August 12, 2016

Skyharbour Closes Non-Brokered Private Placement of $2.47 Million and Granted Exchange Acceptance for the Option to Acquire 100% of Moore Lake Uranium Project from Denison Mines

MarketWire Canada August 12, 2016

BriaCell Announces Non-Brokered Private Placement

Marketwired April 22, 2016

BriaCell Announces Proposed Investment by Leading US Biotech Fund

Marketwired April 22, 2016

BriaCell Files a Patent Application to Protect Additional Cancer Vaccines With Genetic Features Thought to Promote Strong Anti-Tumor Activity

Marketwired April 12, 2016

BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter

Marketwired April 5, 2016

BriaCell Discovers Gene Signature of BriaVax(TM) Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial

Marketwired March 29, 2016

BriaCell Announces Senior Management Change

Marketwired March 24, 2016

BioNap Consulting's Jason Napodano Interviewed by The Life Sciences Report

Marketwired December 18, 2015

IIROC Trading Resumption - BCT

Canada NewsWire November 4, 2015

IIROC Trade Resumption - BriaCell Therapeutics Corp.

Newsfile November 4, 2015

BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients

Marketwired November 4, 2015

IIROC Trade Halt - BriaCell Therapeutics Corp.

Newsfile November 4, 2015

IIROC Trading Halt - BCT

Canada NewsWire November 4, 2015

BriaCell Therapeutics to Present at 14th Annual BIO Investor Forum in San Francisco

Marketwired October 19, 2015

BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax(TM) Phase I/IIa Clinical Trial

Marketwired October 8, 2015

BriaCell Executives Interviewed by The Life Sciences Report

Marketwired October 1, 2015

BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM)

Marketwired September 14, 2015

Immuno-Oncology Biotech BriaCell Attracts Top Scientist to Head R&D

Marketwired July 15, 2015

BriaCell Therapeutics Begins Trading on the OTCQB (ANCCF) and Presents at a New York Biotech Investor Conference

Marketwired June 24, 2015